Yildiray Yildiz, Department of Urology, Clinic of Ankara Training and Research Hospital, Ankara, Turkey
Veysel Bayburtluoglu, Department of Urology, Clinic of Ankara Training and Research Hospital, Ankara, Turkey
Eda Tokat, Department of Urology, Clinic of Ankara Training and Research Hospital, Ankara, Turkey
Ali K. Yildiz, Department of Urology, Clinic of Ankara Training and Research Hospital, Ankara, Turkey
Aykut Ucar, Department of Urology, Clinic of Ankara Training and Research Hospital, Ankara, Turkey
Sebnem Erdinc, Department of Infectious Diseases and Clinical Microbiology University of Medical Sciences, Clinic of Ankara Training and Research Hospital, Ankara, Turkey
Omer G. Doluoglu, Department of Urology, Clinic of Ankara Training and Research Hospital, Ankara, Turkey
Objectives: To evaluate changes in prostate-specific antigen (PSA) values in patients with coronavirus disease 2019 (COVID-19). Method: Male patients who were admitted to our flu outpatient clinic with cough, fever, weakness, and bone and joint pain were evaluated. The acute phase reactants of erythrocyte sedimentation rate, C-reactive protein, ferritin, and fibrinogen were measured both at the time the patients first presented at the clinic and 1 month after recovery from COVID-19 infection. PSA and free PSA were also measured at the same time. The difference in acute phase reactants and PSA values during active COVID-19 infection and after recovery was assessed using the paired samples t-test. Results: The mean PSA values of the patients were 2.73 ± 3.7 μg/L in the period of active infection, and 2.04 ± 2.32 μg/L 1 month later (p = 0.12). In the 29 patients with PSA values in the gray zone, the PSA values were determined as 6.6 ± 4.4 μg/L during infection and 4.1 ± 2.9 μg/L after treatment (p = 0.001). Conclusion: The results of this study showed that PSA values in the gray zone during COVID-19 infection decreased after treatment when the patient recovered.
Keywords: COVID-19. Infection. Prostate. Prostate-specific antigen.